MLLT10 in benign and malignant hematopoiesis

Jamie L Deutsch; Jessica L Heath

doi:10.1016/j.exphem.2020.06.002

MLLT10 in benign and malignant hematopoiesis

Exp Hematol. 2020 Jul:87:1-12. doi: 10.1016/j.exphem.2020.06.002. Epub 2020 Jun 20.

Authors

Jamie L Deutsch¹, Jessica L Heath²

Affiliations

¹ Department of Pediatrics, University of Vermont, Burlington, VT.
² Department of Pediatrics, University of Vermont, Burlington, VT; Department of Biochemistry, University of Vermont, Burlington, VT 05405; University of Vermont Cancer Center, Burlington, VT. Electronic address: jheath1@med.uvm.edu.

PMID: 32569758
DOI: 10.1016/j.exphem.2020.06.002

Abstract

Non-random chromosomal translocations involving the putative transcription factor Mixed Lineage Leukemia Translocated to 10 (MLLT10, also known as AF10) are commonly observed in both acute myeloid and lymphoid leukemias and are indicative of a poor prognosis. Despite the well-described actions of oncogenic MLLT10 fusion proteins, the role of wild-type MLLT10 in hematopoiesis is not well characterized. The protein structure and several interacting partners have been described and provide indications as to the potential functions of MLLT10. This review examines these aspects of MLLT10, contextualizing its function in benign and malignant hematopoiesis.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Hematopoiesis*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Neoplasm Proteins / metabolism*
Transcription Factors / metabolism*

Substances

MLLT10 protein, human
Neoplasm Proteins
Transcription Factors